{"id":746177,"date":"2023-04-10T08:03:52","date_gmt":"2023-04-10T12:03:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-to-present-at-22nd-annual-needham-virtual-healthcare-conference\/"},"modified":"2023-04-10T08:03:52","modified_gmt":"2023-04-10T12:03:52","slug":"rhythm-pharmaceuticals-to-present-at-22nd-annual-needham-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-to-present-at-22nd-annual-needham-virtual-healthcare-conference\/","title":{"rendered":"Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference"},"content":{"rendered":"
\n

BOSTON, April 10, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the 22nd<\/sup> Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 3:00 p.m. ET.<\/p>\n

A live audio webcast of the presentation will be available under \u201cEvents & Presentations\u201d in the Investor Relations section of the Company\u2019s website at www.rhythmtx.com<\/a>. A replay of the webcast will be available on the Rhythm website for 30 days following the presentation.<\/p>\n

\n About\u00a0Rhythm Pharmaceuticals<\/strong>
\n
Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. Rhythm\u2019s lead asset, IMCIVREE (setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases, is approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to pro-opiomelanocortin (POMC), proprotein convertase subtilisin\/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency confirmed by genetic testing, or patients with a clinical diagnosis of Bardet-Biedl syndrome (BBS). Both the European Commission (EC) and the UK\u2019s Medicines & Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 6 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. Rhythm\u2019s headquarters is in Boston, MA.<\/p>\n

\n Setmelanotide Indication<\/strong>
\n
In\u00a0the\u00a0United States, setmelanotide is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to POMC, PCSK1 or LEPR deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1 or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) or BBS.<\/p>\n

In the\u00a0European Union, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) or genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above.<\/p>\n

\n Limitations of Use<\/strong>
\n
In\u00a0the United States\u00a0and\u00a0Europe, Setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.<\/p>\n

Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:<\/p>\n